Xilaplus®, a first assignment for Sandoz

We help Sandoz, a division within Novartis, with a first assignment. It concerns salesbriefing of the product Xilaplus® to selected pharmacies. Xilaplus® is a new effektive acute treatment for diarrhea. Without the side effect of interfering with the intestine, which means that Xilaplus® does not affect the normal movements of the intestine but instead immediately creates a protective barrier that stops the cause of the diarrhea. Effectively and gently.

Posted in category: